NEWS FivepHusion Announces Successful Type C Meeting with the FDA regarding the Deflexifol™ Clinical Development, CMC and Regulatory Paths for mCRCJanuary 18, 2023Read MoreStrategic Collaboration with the University of South Australia, Successful Over-Subscribed Capital Raising and Non-Dilutive FundingNovember 30, 2022Read MoreIndependent Data Safety Monitor Recommends Deflexifol™ Dose Escalation after Review of Promising Clinical ResultsJanuary 31, 2022Read MoreFivepHusion Announces Establishment of an Independent Expert Clinical Advisory BoardJanuary 18, 2022Read More
